Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin

Ai,Yaowei; Zhou,Qiaohui; Li,Ling; Pan,Zhihong; Guo,Mingwen; Han,Jingbo

doi:10.3892/ol.2017.7693

Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin

Authors:
- Yaowei Ai
- Qiaohui Zhou
- Ling Li
- Zhihong Pan
- Mingwen Guo
- Jingbo Han
View Affiliations

Affiliations: Department of Gastroenterology, The First People's Hospital of Yichang, China Three Georges University, Yichang, Hubei 443000, P.R. China, Department of Anesthesiology, Ren He Hospital of Three Gorges University, Yichang, Hubei 443000, P.R. China
Published online on: December 27, 2017 https://doi.org/10.3892/ol.2017.7693
Pages: 3185-3191

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance inhibits the efficacy of doxorubicin in gastric cancer. Phosphatidylinositol 3,4,5‑trisphosphate RAC exchanger 2a (P-REX2a) activates the phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt) signaling pathway by binding to and inactivating phosphatase and tensin homolog (PTEN), which functions as a tumor promoter in a number of types of cancer. However, there is no research concerning the association between P‑REX2a expression and drug resistance in gastric cancer. In the present study, the expression of P‑REX2a in clinical gastric cancer tissues was detected, and the mechanism of doxorubicin resistance in the gastric cancer cell line SGC7901 was investigated. Using reverse transcription‑quantitative polymerase chain reaction and western blotting, it was demonstrated that the mRNA and protein expression of P‑REX2a was increased in gastric cancer tissues. MTT assays were also used to determine proliferation, and proliferation was revealed to be reduced following transfection of P‑REX2a small interfering (si)RNA. When the cells were treated with 0.3 µM doxorubicin for 24 h, the rate of apoptosis in the siRNA‑transfected groups significantly increased and no marked changes in of PTEN and Akt expression were observed. By contrast, the activity of PTEN increased, and the expression of p‑Akt (S473) decreased in the P‑REX2a siRNA‑transfected group compared with the control. The detection of PTEN enzymatic activity in the present study was based on phosphatidylinositol-3,4,5-trisphosphate. Therefore, it was concluded that P‑REX2a may participate in the generation of resistance to doxorubicin in gastric cancer, and this may be associated with the upregulation of the PI3K/Akt signaling pathway via inactivation of PTEN.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sun X, Bao J and Shao Y: Mathematical modeling of therapy-induced cancer drug resistance: Connecting cancer mechanisms to population survival rates. Sci Rep. 6:224982016. View Article : Google Scholar : PubMed/NCBI
4	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
5	Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, et al: Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 520:368–372. 2015. View Article : Google Scholar : PubMed/NCBI
6	Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M, Huang P and Yu D: Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res. 26:564–572. 2014.PubMed/NCBI
7	Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 30:773–782. 2013. View Article : Google Scholar : PubMed/NCBI
8	Eng C: PTEN: One gene, many syndromes. Hum Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
9	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, et al: Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science. 325:1261–1265. 2009. View Article : Google Scholar : PubMed/NCBI
11	Leslie NR: P-REX2a driving tumorigenesis by PTEN inhibition. Sci Signal. 2:pe682009. View Article : Google Scholar : PubMed/NCBI
12	Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 122:433–443. 2008. View Article : Google Scholar : PubMed/NCBI
13	Fu XQ, Yu JP, Luo HS and Yu HG: The expression and role of PTEN in doxorubicin induced gastric cancer cell apoptosis. Zhonghua Nei Ke Za Zhi. 49:422–425. 2010.(In Chinese). PubMed/NCBI
14	Schmidt N, Peitz U, Lippert H and Malfertheiner P: Missing gastric cancer in dyspepsia. Aliment Pharmacol Ther. 21:813–820. 2005. View Article : Google Scholar : PubMed/NCBI
15	Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 15:1389–1396. 2014. View Article : Google Scholar : PubMed/NCBI
16	Yu BQ and Xie JW: Identifying therapeutic targets in gastric cancer: The current status and future direction. Acta Biochim Biophys Sin (Shanghai). 48:90–96. 2016.PubMed/NCBI
17	Ai YW, Yu HG, Yu JP, Yang Y, Li H, Hu XW and Luo HS: Impact of PI3K/Akt/mdm2 signaling pathway on the sensitivity of gastric cancer cell line SGC7901 to doxorubicin. Zhonghua Zhong Liu Za Zhi. 30:494–497. 2008.(In Chinese). PubMed/NCBI
18	Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J, Zhi X and Zhang J: Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis. 6:e20202015. View Article : Google Scholar : PubMed/NCBI
19	Smolensky D, Rathore K and Cekanova M: Phosphatidylinositol-3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro. BMC Cancer. 15:9272015. View Article : Google Scholar : PubMed/NCBI
20	Wang Z, Yang L, Xia Y, Guo C and Kong L: Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway. Biol Pharm Bull. 38:277–284. 2015. View Article : Google Scholar : PubMed/NCBI
21	Donald S, Hill K, Lecureuil C, Barnouin R, Krugmann S, John Coadwell W, Andrews SR, Walker SA, Hawkins PT, Stephens LR and Welch HC: P-Rex2, a new guanine-nucleotide exchange factor for Rac. FEBS Lett. 572:172–176. 2004. View Article : Google Scholar : PubMed/NCBI
22	Guo B, Liu L, Yao J, Ma R, Chang D, Li Z, Song T and Huang C: miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
23	Goler-Baron V, Sladkevich I and Assaraf YG: Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 83:1340–1348. 2012. View Article : Google Scholar : PubMed/NCBI
24	Fan QW and Weiss WA: Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol. 347:279–296. 2010.PubMed/NCBI
25	Rasul A, Khan M, Yu B, Ali M, Bo YJ, Yang H and Ma T: Isoalantolactone, a sesquiterpene lactone, induces apoptosis in SGC-7901 cells via mitochondrial and phosphatidylinositol kinase/Akt signaling pathways. Arch Pharm Res. 36:1262–1269. 2013. View Article : Google Scholar : PubMed/NCBI